Overview

A Treatment Study Protocol for Participants 1-45 Years With Acute Lymphoblastic Leukaemia

Status:
Recruiting
Trial end date:
2032-06-30
Target enrollment:
Participant gender:
Summary
ALLTogether collects the experience of previously successful treatment of children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised and interventional trials included in the study-design.
Phase:
Phase 3
Details
Lead Sponsor:
Mats Heyman
Collaborators:
Aamu Pediatric Cancer Foundation
Acreditar - Associação de Pais e Amigos das Crianças com Cancro
Amgen
Belgium Health Care Knowledge Centre
Cancer Research UK
Clinical Trial Center North (CTC North GmbH & Co. KG)
Danish Cancer Society
Danish Child Cancer Foundation
Fundação Rui Osório de Castro
Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany
Grupo Português De Leucemias Pediátricas
Karolinska Institutet
NordForsk
Nova Laboratories Limited
Pfizer
Servier
The Novo Nordic Foundation
The Swedish Childhood Cancer Foundation
The Swedish Research Council
Treatments:
BB 1101
Blinatumomab
Dexamethasone
Dexamethasone acetate
Doxorubicin
Imatinib Mesylate
Inotuzumab Ozogamicin
Liposomal doxorubicin
Thioguanine
Vincristine